{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-019338","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.932025+00:00","generated_at":"2026-06-05T17:09:47.583838+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reneo Pharma to cut ~20% workforce, expects $1.7M severance charges in Q1 2024","bullets":["Second workforce reduction of approximately 20% to be completed by February 29, 2024.","Estimated $1.7 million in cash severance and employee termination costs in Q1 2024.","Follows prior reduction announced December 14, 2023 as part of cost-saving plan.","Actual charges may differ due to assumptions and potential additional costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-019338","json":"https://secwatch.observer/filing/0000950170-24-019338.json","markdown":"https://secwatch.observer/filing/0000950170-24-019338.md","text":"https://secwatch.observer/filing/0000950170-24-019338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024019338/0000950170-24-019338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024019338/rphm-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T17:09:47.583838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4daa4755c7a10be97756e93b34990917669e25d9","claim":"OnKure Therapeutics, Inc. announced a restructuring with charges of approximately $1.7 million (approximately 20%).","evidence_excerpt":"the Company expects to complete a second workforce reduction of approximately 20% on February 29, 2024 (the “Second Reduction”). In connection with the Second Reduction, the Company estimates that it will incur charges of approximately $1.7 million associated with cash severance payments and other employee termination-related costs in the first quarter of 2024.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024019338/0000950170-24-019338-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.7 million"},{"label":"Headcount","value":"approximately 20%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}